Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA4 | P22748 | 1/20 | 0.48 |
| ▸ | CA7 | P43166 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.48 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.47 |
| ▸ | PYGL | P06737 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 2/20 | 0.42 |
| ▸ | DRD3 | P35462 | 2/20 | 0.42 |
| ▸ | HTR2C | P28335 | 2/20 | 0.42 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.42 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.41 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.41 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2107235 | 0.78 | NPC1 (0.59) | CA12CA9PYGLKDM4E | |
| SCHEMBL2109176 | 0.78 | CA12 (0.52) | CA12CA9PYGLKDM4ENHERF1 | |
| SCHEMBL2107996 | 0.77 | PYGL (0.51) | CA9PYGLKDM4EALDH1A1MTNR1A | |
| SCHEMBL2606804 | 0.75 | NPC1 (0.50) | CA12CA9HRH4PYGLALDH1A1 | |
| SCHEMBL2606888 | 0.74 | CNR1 (0.60) | CA12CA9HRH4PYGLKDM4E | |
| SCHEMBL2106964 | 0.74 | PYGL (0.52) | CA12CA9PYGL | |
| SCHEMBL2106985 | 0.73 | PYGL (0.52) | PYGL | |
| SCHEMBL2106190 | 0.73 | MEN1 (0.52) | KDM4EMTNR1AMTNR1B | |
| SCHEMBL2107385 | 0.72 | CNR1 (0.56) | CA12CA9KDM4EHDAC3HDAC4 | |
| SCHEMBL13271660 | 0.72 | CNR1 (0.55) | CA12CA9HRH4KDM4EHDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8158622-B2 | Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase | PROSIDION LIMITED (GB) | 2012-04-17 | — | — | US | disclosed |
| US-8158622-B2 | Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase | PROSIDION LIMITED (GB) | 2012-04-17 | — | — | US | disclosed |
| US-8158622-B2 | Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase | PROSIDION LIMITED (GB) | 2012-04-17 | — | — | US | disclosed |
| EP-1636224-B1 | PYRROLOPYRIDINE-2-CARBOXYLIC ACID AMIDE INHIBITORS OF GLYCOGEN PHOSHORYLASE | PROSIDION LTD (GB) | 2010-07-14 | — | — | EP | disclosed |
| US-20090023703-A1 | Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase | PROSIDION LIMITED (GB) | 2009-01-22 | — | — | US | disclosed |
| US-20090023703-A1 | Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase | PROSIDION LIMITED (GB) | 2009-01-22 | — | — | US | disclosed |
| US-7405210-B2 | Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase | OSI PHARMACEUTICALS, INC. (US) | 2008-07-29 | — | — | US | disclosed |
| US-7405210-B2 | Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase | OSI PHARMACEUTICALS, INC. (US) | 2008-07-29 | — | — | US | disclosed |
| US-20070244090-A9 | PYRROLOPYRIDINE-2-CARBOXYLIC ACID AMIDE INHIBITORS OF GLYCOGEN PHOSPHORYLASE | BRADLEY STUART E | 2007-10-18 | — | — | US | disclosed |
| US-20070244090-A9 | PYRROLOPYRIDINE-2-CARBOXYLIC ACID AMIDE INHIBITORS OF GLYCOGEN PHOSPHORYLASE | BRADLEY STUART E | 2007-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070244090-A9 | PYRROLOPYRIDINE-2-CARBOXYLIC ACID AMIDE INHIBITORS OF GLYCOGEN PHOSPHORYLASE | PYGL, PYGM, PYGB | CA12 2211/4885CA4 1107/4885CA7 809/4885 |
| US-20090023703-A1 | Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase | PYGL, PYGM, PYGB | CA12 2211/4885CA4 1107/4885CA7 809/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.